Allogene Therapeutics Inc (ALLO)

$2.72 -0.19 (-6.53%)
Market Cap 663.08M
Revenue (ttm) 0.00
Net Income (ttm) -190.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 8,400,300
Avg Vol 5,824,078
Day's Range N/A - N/A
Shares Out 243.78M
Stochastic %K 69%
Beta 0.53
Analysts Strong Sell
Price Target $7.30

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 2700
Address:
210 East Grand Avenue, South San Francisco, United States
HumblKing
HumblKing Apr. 13 at 2:55 PM
$ALLO just keeps selling
0 · Reply
ASKING7
ASKING7 Apr. 13 at 2:54 PM
$ALLO sold, reminded me last time it was a quick pump as well
0 · Reply
topstockalerts
topstockalerts Apr. 13 at 2:53 PM
Top Gainers PT2 $ALMU $ALLO $SAFX $JDZG $RVMD
0 · Reply
bullcrab85
bullcrab85 Apr. 13 at 2:50 PM
$ALLO this deserves 💯
0 · Reply
Deblitorator
Deblitorator Apr. 13 at 2:46 PM
MBAI swinging this inot the merger easy $ $VRAX keep watch if this holds .17 $ALMU STEADY UPTREND in play. $ALLO MOMENTUM DYING
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 13 at 2:46 PM
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ $ALLO https://stocktwits.com/news/equity/markets/allo-stock-2year-high-biggest-intraday-gain-cancer-treatment-data/cZJ8G6sRIuK
0 · Reply
AlphaResearchFlow
AlphaResearchFlow Apr. 13 at 2:38 PM
$ALLO Allogene Therapeutics a biotech developing cancer cell therapies
0 · Reply
bullcrab85
bullcrab85 Apr. 13 at 2:36 PM
$ALLO this will go up high!!!
1 · Reply
Bullbear1010101
Bullbear1010101 Apr. 13 at 2:35 PM
$ALLO out 3.93
0 · Reply
Bullbear1010101
Bullbear1010101 Apr. 13 at 2:35 PM
$ALLO quite small 3.88
0 · Reply
Latest News on ALLO
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Apr 13, 2026, 8:00 AM EDT - 2 hours ago

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

NTRA

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Apr 13, 2026, 7:30 AM EDT - 3 hours ago

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Apr 10, 2026, 4:02 PM EDT - 2 days ago

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Mar 12, 2026, 4:02 PM EDT - 4 weeks ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Mar 2, 2026, 8:30 AM EST - 6 weeks ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Feb 5, 2026, 8:30 AM EST - 2 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Jan 8, 2026, 8:30 AM EST - 3 months ago

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Dec 15, 2025, 5:39 PM EST - 4 months ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

CLLS

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Nov 6, 2025, 4:05 PM EST - 5 months ago

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Nov 3, 2025, 9:04 AM EST - 5 months ago

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Oct 30, 2025, 8:30 AM EDT - 5 months ago

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 27, 2025, 8:30 AM EDT - 8 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 6, 2025, 8:30 AM EDT - 8 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Aug 1, 2025, 8:30 AM EDT - 9 months ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Jun 1, 2025, 10:45 AM EDT - 11 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025, 5:17 PM EDT - 11 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 13, 2025, 4:05 PM EDT - 11 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

May 6, 2025, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:12 AM EDT - 1 year ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Apr 7, 2025, 8:30 AM EDT - 1 year ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 13, 2025, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 26, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 25, 2025, 4:10 PM EST - 1 year ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Feb 13, 2025, 4:30 PM EST - 1 year ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Jan 28, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Dec 12, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 19, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 18, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 4:02 PM EST - 1 year ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 7, 2024, 10:00 AM EST - 1 year ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2024, 9:10 AM EST - 1 year ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:47 PM EDT - 2 years ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 13, 2024, 4:01 PM EDT - 2 years ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 6, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Apr 26, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Allogene Therapeutics Announces Q2 Investor Conference Participation

Apr 9, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics Announces Q2 Investor Conference Participation

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Mar 5, 2024, 8:30 AM EST - 2 years ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

HumblKing
HumblKing Apr. 13 at 2:55 PM
$ALLO just keeps selling
0 · Reply
ASKING7
ASKING7 Apr. 13 at 2:54 PM
$ALLO sold, reminded me last time it was a quick pump as well
0 · Reply
topstockalerts
topstockalerts Apr. 13 at 2:53 PM
Top Gainers PT2 $ALMU $ALLO $SAFX $JDZG $RVMD
0 · Reply
bullcrab85
bullcrab85 Apr. 13 at 2:50 PM
$ALLO this deserves 💯
0 · Reply
Deblitorator
Deblitorator Apr. 13 at 2:46 PM
MBAI swinging this inot the merger easy $ $VRAX keep watch if this holds .17 $ALMU STEADY UPTREND in play. $ALLO MOMENTUM DYING
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 13 at 2:46 PM
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ $ALLO https://stocktwits.com/news/equity/markets/allo-stock-2year-high-biggest-intraday-gain-cancer-treatment-data/cZJ8G6sRIuK
0 · Reply
AlphaResearchFlow
AlphaResearchFlow Apr. 13 at 2:38 PM
$ALLO Allogene Therapeutics a biotech developing cancer cell therapies
0 · Reply
bullcrab85
bullcrab85 Apr. 13 at 2:36 PM
$ALLO this will go up high!!!
1 · Reply
Bullbear1010101
Bullbear1010101 Apr. 13 at 2:35 PM
$ALLO out 3.93
0 · Reply
Bullbear1010101
Bullbear1010101 Apr. 13 at 2:35 PM
$ALLO quite small 3.88
0 · Reply
AS1980
AS1980 Apr. 13 at 2:32 PM
$ALLO I don’t care about shorts to cover now I only care about longs to come Company and science is now de-risked And that’s a crucial point for BO offers to come
0 · Reply
bullcrab85
bullcrab85 Apr. 13 at 2:32 PM
$ALLO
1 · Reply
bullcrab85
bullcrab85 Apr. 13 at 2:30 PM
$ALLO
0 · Reply
Verdelechugita
Verdelechugita Apr. 13 at 2:29 PM
A few years ago, $BLIN was trading above $10 per share; it's incredible to see it below $1 and now being a better company. One day he will awaken with great strength (personal opinion) 💪💣 Let's go! up 🔝 Today is a good day to $RMSG , $RCT , $ALLO and $ALMU up 🚀
0 · Reply
Packland
Packland Apr. 13 at 2:28 PM
$ALLO
0 · Reply
M105
M105 Apr. 13 at 2:26 PM
$ALLO $17.24 incoming
1 · Reply
bullcrab85
bullcrab85 Apr. 13 at 2:26 PM
$ALLO
0 · Reply
AS1980
AS1980 Apr. 13 at 2:25 PM
$ALLO should be at 5-6 range now
0 · Reply
Mr_JokeR
Mr_JokeR Apr. 13 at 2:24 PM
$ALLO multi day runner. Lfg
0 · Reply
TacticalSwings
TacticalSwings Apr. 13 at 2:22 PM
Was in some of @MetricWhale plays recently that went hard! Give him a follow 🔥 $RCT $RECT $ALLO Real winners today.
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 13 at 2:21 PM
WATCHLIST AT OPEN Here’s the lineup for today’s action. Keep these on your radar: 👉Click to view @NasdaqPulse for timely updates amid the volatility. $SOAR - Merger Play; must hold .28 for a solid move $RMSG - Tiny float; scalp opportunities LIVE; watching for a halt up at open $RVMD - Huge PR, big float, massive spike potential → Phase 3 for Metastatic Pancreatic Cancer $ALLO - Trial in Large B-Cell Lymphoma $SAFX - Swing setup from .62; needs to break $1+ and hold; next bounce at .88 UONE - Premarket scanner hit; tiny float, big move incoming NIXX - Dip buys for a swing; volume's dead for now but could pop ORBS - Scale into .80 for a swing ELAB - Multiple PRs; must hold $5 to continue upward momentum RCT - Big deal! $30M Saudi licensing agreement with RedCloud VRAX - Must hold .18 for the next leg up And don't forget the Oilers: BATL, TMDE, ANNA, EONR, etc. Buckle up for a long week of volatility and opportunity! Let’s see who’s ready to move.
0 · Reply
topstockalerts
topstockalerts Apr. 13 at 2:21 PM
$ALLO holding up strong 💪
0 · Reply